GlassScriptPhysician profile
Taiwo Adeogun
NPI 1679802938
$3,159.55
in general payments reported to CMS, 2019-2025
24 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $945 · 2022: $942 · 2024: $673 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.92 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.58 | 2021-2025 | |
| Alkermes, INC. | $271.68 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $232.10 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $217.16 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $199.24 | 2021-2024 | Fanapt |
| Neos Therapeutics, LP | $165.06 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.56 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $154.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $110.80 | 2022-2024 | Austedo Xr, Uzedy |
| Jazz Pharmaceuticals INC. | $89.29 | 2021-2022 | |
| Almatica Pharma LLC | $82.22 | 2021-2025 | Loreev Xr |
| Lundbeck LLC | $65.71 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $63.31 | 2024-2025 | Ingrezza |
| Bausch Health US, LLC | $57.14 | 2022-2025 | Aplenzin |
| Corium, LLC | $43.21 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $42.80 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $37.92 | 2021-2022 | |
| Aytu Biopharma, INC. | $36.44 | 2021 | |
| Ironshore Pharmaceuticals INC. | $36.26 | 2022 | |
| Avanir Pharmaceuticals, INC. | $32.47 | 2021 | |
| Noven Therapeutics, LLC | $24.91 | 2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $21.28 | 2025 | Relexxii |
| Eisai INC. | $18.26 | 2021 | |
| Tris Pharma INC | $15.64 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taiwo Adeogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.